1.
RSC Adv
; 13(22): 15322-15326, 2023 May 15.
Article
in English
| MEDLINE | ID: covidwho-2324348
ABSTRACT
We have developed broadly reactive aptamers against multiple variants by alternating the target between spike proteins from different SARS-CoV-2 variants during the selection process. In this process we have developed aptamers which can recognise all variants, from the original wild-type 'Wuhan' strain to Omicron, with high affinity (Kd values in the pM range).